Dr. Grey AI

Invasive Aspergillosis

Life-threatening fungal infection caused by Aspergillus species, primarily affecting immunocompromised patients. Most commonly involves lungs but can disseminate to brain, heart, and other organs. High mortality (30-95%) depending on host factors and treatment timing.

Quick Answer

What it is

Life-threatening fungal infection caused by Aspergillus species, primarily affecting immunocompromised patients. Most commonly involves lungs but can disseminate to brain, heart, and other organs.

Key findings

  • Grade B: Invasive Aspergillosis (Salvage) (Caspofungin (Cancidas))

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

ℹ️ Quick Facts

Quick Facts: Invasive Aspergillosis

  • Supplements Studied:1
1 supps · 1 outcomes

Detailed Outcomes

B
Invasive Aspergillosis (Salvage)
FDA-approved for refractory invasive aspergillosis based on Phase 2 trial (<100 patients). Response in patients failing other antifungals. Fungistatic mechanism limits first-line use.
moderate↑Improves

Research Citations (42)

Efficacy and safety of voriconazole and caspofungin for the treatment of invasive pulmonary aspergillosis in critically ill patients in China.
(2025)
PMID: 40470260
Rezafungin vs caspofungin for the treatment of invasive candidiasis: A systematic review and meta-analysis.
(2025)
PMID: 40651396
Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection.
(2023)
PMID: 37328748
Efficacy and safety of caspofungin for patients with hepatic insufficiency.
(2022)
PMID: 35725403
Pharmacokinetics/Pharmacodynamics of Caspofungin in Plasma and Peritoneal Fluid of Liver Transplant Recipients.
(2022)
PMID: 34662185
Caspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety.
(2021)
PMID: 32845461
Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.
(2021)
PMID: 33277811
Factors influencing caspofungin plasma concentrations in kidney transplant patients with high incidence of invasive fungal infections.
(2020)
PMID: 31468555
Caspofungin: a review of its characteristics, activity, and use in intensive care units.
(2020)
PMID: 32662712
Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.
(2019)
PMID: 30672611

Related Conditions

Candidemia and Invasive Candidiasis

1 shared supplement · 17 outcomes

Bloodstream infection (candidemia) and deep-tissue infections caused by Candida species. A serious healthcare-associated infection with mortality rates of 30-50%. Most commonly caused by C. albicans, C. glabrata, and C. tropicalis. Requires systemic antifungal therapy.